ALT-100 clinical trials
Also written ALT-100.
How each study uses ALT-100 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ALT-100 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ALT-100
- 2
Studies by the year they started
2 studies that test it; most in 2022 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Aqualung Therapeutics Corp. (2) · University of Florida (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ALT-100.
- May 2027Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDSPhase 2 · Aqualung Therapeutics Corp.
Studies
Open first, then newest update. How each study uses ALT-100 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The ALTAR-100 TrialNot yet recruitingPhase 1/2University of FloridaNCT07917390Written as ALT-100
- Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDSActive, not recruitingPhase 2Aqualung Therapeutics Corp.NCT05938036Written as ALT-100 mAb
- First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100CompletedPhase 1Aqualung Therapeutics Corp.NCT05426746Written as ALT-100